88 related articles for article (PubMed ID: 18173065)
1. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab.
Halaburda K; Nasiłowska-Adamska B; Grabarczyk P; Szczepiński A; Szpila T; Warzocha K; Mariańska B
Ann Transplant; 2007; 12(2):37-40. PubMed ID: 18173065
[TBL] [Abstract][Full Text] [Related]
2. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
[TBL] [Abstract][Full Text] [Related]
4. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
Scheinberg P; Fischer SH; Li L; Nunez O; Wu CO; Sloand EM; Cohen JI; Young NS; John Barrett A
Blood; 2007 Apr; 109(8):3219-24. PubMed ID: 17148582
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
6. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
[TBL] [Abstract][Full Text] [Related]
7. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
Song WK; Min YH; Kim YR; Lee SC
Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
11. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
13. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
14. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation.
Gentile G; Picardi A; Capobianchi A; Spagnoli A; Cudillo L; Dentamaro T; Tendas A; Cupelli L; Ciotti M; Volpi A; Amadori S; Martino P; de Fabritiis P
BMC Infect Dis; 2006 Nov; 6():167. PubMed ID: 17118205
[TBL] [Abstract][Full Text] [Related]
15. Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation.
Pumannova M; Roubalova K; Vitek A; Sajdova J
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):115-20. PubMed ID: 16406183
[TBL] [Abstract][Full Text] [Related]
16. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
[TBL] [Abstract][Full Text] [Related]
17. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
18. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Marchesi F; Pimpinelli F; Dessanti ML; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Maschio M; Ensoli F; Mengarelli A
Transpl Infect Dis; 2014 Dec; 16(6):1032-8. PubMed ID: 25369809
[TBL] [Abstract][Full Text] [Related]
20. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.
Bainton RD; Byrne JL; Davy BJ; Russell NH
Blood; 2002 Nov; 100(10):3843-4. PubMed ID: 12411329
[No Abstract] [Full Text] [Related]
[Next] [New Search]